Skip to content

Reliable detection and quantification of DNA for HPV 16 and 18

HPV-SEQ detects and quantifies cell-free HPV 16 and 18 DNA (cfHPV-DNA) across a large dynamic range and demonstrates accurate quantification even when few copies are present.

HPV-SEQ enables high-resolution molecular monitoring of patients with HPV-driven cancers.

Several studies are underway using HPV-SEQ to de-escalate HPV-driven cancer treatment to reduce toxicities without compromising survival outcomes. Assessment of quantitative cfHPV-DNA in the convenient biomarker-driven strategy to guide personalized treatment in HPV-positive oropharyngeal cancer (OPC).1

“The ability to reliably detect HPV-DNA in plasma at such low frequency shows HPV-SEQ could be a promising non-invasive biomarker test for effectively assessing treatment response, appropriately de-intensifying treatment using real-time dynamic HPV quantification, and monitoring HPV-positive OPC patients’ post-treatment. Therefore, the HPV-SEQ test has the potential to be an important tool for oncologists in treating patients with HPV-associated head and neck cancer,” he concluded.2

Dr. Nishant Agrawal,
Professor of Surgery at the University of Chicago.

Panel features

CLIA-validated, ultra-sensitive quantitative blood test for the detection of cell-free HPV 16 and 18 DNA (cfHPV-DNA, this panel detects as few as two HPV 16 and 18 molecules in a background of 30,000 wild-type molecules (0.03% allele frequency).

For clinicians only

Order patient test

We’d love to hear from you!


  1. Rosenberg A, Izumchenko E, Pearson A, Gooi Z, et al. Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment. BMC Cancer. 2022. 3;22(1):17. doi: 10.1186/s12885-021-09146-z.
  2. Sysmex Inostics Press Release, January 26, 2022